Pharma marketing is undergoing a major transformation as brands move away from broad, unfocused campaigns and embrace data-driven strategies that reach patients who are most likely to benefit from treatment, said Steve Silvestro, CEO of OptimizeRx. Speaking with Fierce Pharma Publisher Rebecca Willumson, Silvestro pointed to real-time AI and machine learning platforms that predict “brand eligible” patients and deliver coordinated messaging to physicians and patients simultaneously. He said the shift marks a decisive break from the traditional “spray and pray” model as companies increasingly measure ROI and conversion impact.
Silvestro also emphasized how these advances in marketing support earlier diagnosis and intervention, citing an OptimizeRx project that helped triple-negative breast cancer patients begin therapy eight to nine months sooner than average, extending life expectancy by more than a year. For marketers, he added, success depends on understanding the patient journey, navigating shifting marketing mixes, and leveraging new technologies to advocate for their brands. To hear Silvestro’s full insights on the challenges and future of pharma marketing, watch the complete interview.